Scott Garland

Mr. Garland is Chief Executive Officer of PACT Pharma. Prior to joining PACT, Mr. Garland was President and CEO of Portola Pharmaceuticals prior to its acquisition by Alexion in July 2020. Prior to joining Portola, Mr. Garland was President of Relypsa, which was acquired by Vifor Pharma in 2016. Prior to Relypsa, Mr. Garland was Executive Vice President and Chief Commercial Officer at Exelixis, where he led the commercial operations and launched cabozantinib. Previously, Mr. Garland spent close to a decade at Genentech, leading full-scale commercial franchises for two top-selling oncology therapies Avastin® and Rituxan®. He started his career at Merck as a sales representative and then went on to serve at Amgen in various sales and marketing roles. Mr. Garland currently serves as a member of the board of directors at Day One Biopharmaceuticals. Mr. Garland has a B.S. in biological sciences from California Polytechnic State University, San Luis Obispo, and an M.B.A. from Duke University’s Fuqua School of Business.